Compugen Ltd.
Compugen Ltd. is a clinical-stage therapeutic discovery and development company.
It has immuno-oncology pipeline with multiple programs in various stages.
These include COM701, COM902, Bapotulimab, Rilvegostomig, and early-stage programs.
The company also has collaborations with Bayer Pharma AG, Bristol-Myers Squibb, and Johns Hopkins School of Medicine.
AstraZeneca has a license agreement for bi-specific and multi-specific immuno-oncology antibody products.
Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
Overview
Strengths
- Our discounted cash flow model points to 65% upside (target price 3.23 USD), and even our pessimistic growth scenario implies 50%: a margin of safety.
- Valued below its Biotechnology peers: P/E 5.2x vs. a median of 20.4x, P/FCF 5.9x vs. a median of 20.2x and EV/EBITDA 3.0x vs. a median of 15.6x.
- Consistent growth: revenue has compounded at 105.2% a year over 5 years, rising in 4 of them.
- ROIC of 29.9% beats 86% of its 128 Biotechnology peers (median 0.0%).
- EBITDA margin of 44.1% beats 87% of its 128 Biotechnology peers (median 0.0%).
- Improving fundamentals over the last year: return on assets up 34.9 points, gross margin up 15.7 points and asset turnover up 91.8%.
Weaknesses
- Unreliable cash generation: free cash flow was negative in 4 of the last 6 years.
- Unstable profitability: operating margin ranged from -1,575% to 43% over the last 6 years, with operating losses in 5 of them.
- Earnings are projected to decline (-10.0% per year).
- Small company (enterprise value $98 million): thinner analyst coverage, lower liquidity and wider valuation uncertainty.
Key Financial Data